Benzodiazepine pharmacodynamics: evidence for biophase rate limiting mechanisms
- PMID: 2883695
- DOI: 10.1007/BF00217057
Benzodiazepine pharmacodynamics: evidence for biophase rate limiting mechanisms
Abstract
Pharmacokinetics do not adequately reflect recovery from cognitive neuromotor impairment induced by most benzodiazepines. This paper examines across time the nature of the relationship of effect to serum concentration of three benzodiazepines. Using the same protocol lorazepam, alprazolam, diazepam and placebo were administered to eight healthy males at doses of 0.057, 0.029, 0.286 and 0.000 mg/kg, body weight, respectively for the first study and at 0.028, 0.014, 0.143 and 0.000 mg/kg, respectively, for the second study. After each dose administration multiple measurements were made over a period of 5.5-11.5 h using two different psychomotor performance tests. Serum drug concentrations were also measured. The profiles for diazepam and alprazolam effects demonstrate a stepwise decrement in the slopes of the concentration versus response curves across time, illustrating the rapid development of acute tolerance. In contrast, lorazepam induced a remarkably constant relationship between concentration and effect across testing intervals.
Similar articles
-
Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam.Psychopharmacology (Berl). 1985;86(4):392-9. doi: 10.1007/BF00427897. Psychopharmacology (Berl). 1985. PMID: 2863843 Clinical Trial.
-
A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam.J Clin Psychopharmacol. 2000 Dec;20(6):628-35. doi: 10.1097/00004714-200012000-00008. J Clin Psychopharmacol. 2000. PMID: 11106134 Clinical Trial.
-
Comparative pharmacodynamics of benzodiazepines.Psychopharmacol Ser. 1987;3:77-82. doi: 10.1007/978-3-642-71288-3_9. Psychopharmacol Ser. 1987. PMID: 2881294 No abstract available.
-
Objective and subjective assessments of the effects of flupentixol and benzodiazepines on human psychomotor performance.Psychopharmacology (Berl). 1988;95(3):323-8. doi: 10.1007/BF00181941. Psychopharmacology (Berl). 1988. PMID: 2901125 Clinical Trial.
-
Benzodiazepines and vigilance performance: a review.Psychopharmacology (Berl). 1989;98(2):145-56. doi: 10.1007/BF00444684. Psychopharmacology (Berl). 1989. PMID: 2569213 Review.
Cited by
-
Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.CNS Drug Rev. 2004 Spring;10(1):45-76. doi: 10.1111/j.1527-3458.2004.tb00003.x. CNS Drug Rev. 2004. PMID: 14978513 Free PMC article. Review.
-
The effects of alprazolam alone and combined with alcohol on central integrative activity.Eur J Clin Pharmacol. 1992;42(5):495-8. doi: 10.1007/BF00314857. Eur J Clin Pharmacol. 1992. PMID: 1606995 Clinical Trial.
-
Residual next-day effects of alprazolam on psychomotor performance and simulated driving in healthy normal adults.Exp Clin Psychopharmacol. 2025 Apr;33(2):178-188. doi: 10.1037/pha0000746. Epub 2024 Nov 14. Exp Clin Psychopharmacol. 2025. PMID: 39541522 Clinical Trial.
-
Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.J Pharm Pharm Sci. 2014;17(1):34-91. J Pharm Pharm Sci. 2014. PMID: 24735761 Free PMC article.
-
Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.Clin Pharmacokinet. 1996 Jan;30(1):52-76. doi: 10.2165/00003088-199630010-00004. Clin Pharmacokinet. 1996. PMID: 8846627 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources